(Press-News.org) Phoenix, AZ (May 19, 2023)- A new study examining the criteria proposed by the European Society of Cardiology (ESC) to prescribe long-term treatment with more than one blood thinner after percutaneous coronary intervention was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions. The study confirmed that patients presenting the characteristics proposed in the ESC guidelines are more likely to experience complications due to blood clotting in the coronary arteries. These patients may therefore benefit from a long-term treatment with more than one blood thinner.
Risk assessment before percutaneous coronary intervention (PCI) provides valuable information for patient management and post-intervention treatment. The latest ESC guidelines for the management of patients with Non-ST-segment elevation acute coronary syndrome, recommend patients with specific high-risk characteristics like a history of myocardial infarction, diabetes, chronic kidney disease or an advanced form of coronary artery disease, might benefit from longer-term treatment with blood thinners after PCI following a heart attack. The use of blood thinners after PCI can help prevent complications like blood clots from forming inside a patient’s stent.
Patients with acute or chronic coronary syndrome undergoing PCI at a large tertiary-care center from 2012 to 2019 were included in the analysis. Patients were grouped into low, medium, and high thrombotic risk based on the ESC criteria. The primary endpoint was major adverse cardiovascular events (MACE) at one year, a composite of all-cause death, myocardial infarction (MI) and stroke. Secondary endpoints included the individual components of the primary endpoint and major bleeding.
Among 11,787, patients included in the study, 2,641 (22.4%) were at low-risk, 5,286 (44.8%) at moderate risk, and 3,860 (32.7%) at high-risk. The one-year risk of MACE was increased in patients at moderate (HR 2.53, 95% CI 1.78-3.58) and high-risk (HR 3.39, 95% CI 2.39-4.80) as compared to those at low-risk, because of higher rates of all-cause death and MI in the two former groups. Major bleeding was significantly higher in high-risk patients (HR 1.59, 95% CI 1.25 – 2.02), but similar between the moderate and low-risk group.
“We see an inherent need to provide individualized cardiology care using precision medicine principles adjusted on patient unique risk factors,” said George Dangas, M.D., Ph.D., MACC, MSCAI, Professor of Cardiology and Vascular Surgery at the Icahn School of Medicine at Mount Sinai, New York, lead author of the study and SCAI President-Elect. “With this study, we are working to find the best way to provide the right blood thinner therapy to the right patient. Evaluating these criteria offers an important step toward the creation of a more personalized tool to identify high-risk patients who would benefit from a long-term treatment with more than one blood thinner.”
Session Details:
“Predictive value of the Thrombotic Risk Criteria of the 2020 ESC guidelines for NSTE-ACS: validation in a large PCI registry” [Friday, May 19, 2023, 3:40– 5:10 PM MST, West 103, First Floor, Phoenix Convention Center]
About SCAI:
The Society for Cardiovascular Angiography & Interventions (SCAI) is a non-profit professional association with over 4,500 members representing interventional cardiologists and cardiac catheterization teams in the United States. SCAI promotes excellence in interventional cardiovascular medicine for both adults and children through education, representation, and the advancement of quality standards to enhance patient care.
For more information about the SCAI 2023 Scientific Sessions, visit https://scai.org/scai-2023-scientific-sessions. Follow @SCAI on Twitter for the latest heart health news and use #SCAI2023 to follow the latest discussions.
###
END
Methane, a greenhouse gas known to do about 80 times more damage to the atmosphere than carbon dioxide over a 20-year period, is often overlooked by policymakers and governments. In a review publishing in the journal One Earth on May 19, researchers analyzed the coverage, stringency, and real-world impact of current global methane emissions policies for the first time. They found that only 13% of emissions are currently covered by direct mitigation policies.
In order to limit climate warming to 1.5 degrees Celsius in accordance with the Paris Agreement, global methane emissions need to be cut by at least 40%–45%, according to the 2021 Global Methane Assessment—a feat that the ...
New research from Queen Mary University of London shows that only around 13% of global methane emissions are regulated, despite methane emissions causing at least 25% of current global warming.
The global review, published on 19 May in One Earth, also found that little is known about the effectiveness of the policies that exist, with potentially unrepresentative methane emission estimations used rather than actual measurements. Inaccurate estimations can also mean the issue is taken less seriously by decision-makers by masking its severity.
The researchers argue that the lack ...
(Philadelphia, PA) – Genetic alterations that give rise to a rare, fatal disorder known as MOGS-CDG paradoxically also protect cells against infection by viruses. Now, scientists at the Lewis Katz School of Medicine at Temple University have harnessed this unusual protective ability in a novel gene-editing strategy aimed at eliminating HIV-1 infection with no adverse effects on cell mortality.
The new approach, described online April 28 in the journal Molecular Therapy – Nucleic Acids, is based on a combination of two gene-editing constructs, one that ...
About The Study: This survey study found that although there has been substantial policy attention around incentivizing COVID-19 vaccination, fewer than 1 in 10 vaccinated individuals in a nationally representative sample of U.S. adults reported receiving an incentive. Most vaccinated respondents reported that an incentive did not make a difference in their decision-making to get the COVID-19 vaccine.
Authors: Laura J. Faherty, M.D., M.P.H., M.S.H.P., of the RAND Corporation in Boston, is the corresponding author.
To access the ...
About The Study: In this decision analytical model, increased uptake of bivalent booster vaccination among eligible age groups was associated with decreased hospitalizations and school absenteeism in the pediatric population. These findings suggest that although COVID-19 prevention strategies often focus on older populations, the benefits of booster campaigns for children may be substantial.
Authors: Alison P. Galvani, Ph.D., of the Yale School of Public Health in New Haven, Connecticut, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this ...
About The Study: In this case-control surveillance study of more than 100,000 pregnancies, COVID-19 booster vaccination in pregnancy was not associated with spontaneous abortion. These findings support the safety of recommendations for COVID-19 booster vaccination, including in pregnant populations.
Authors: Elyse O. Kharbanda, M.D., M.P.H., of HealthPartners Institute in Minneapolis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.14350)
Editor’s ...
HealthPartners Institute researchers have published new data in JAMA Network Open that shows monovalent COVID-19 booster vaccinations administered in early pregnancy (before 20 weeks’ gestation) were not associated with miscarriage. The research adds to the growing understanding about the safety of COVID-19 booster vaccinations among people who are pregnant.
The researchers analyzed data from more than 100,000 pregnancies between six and 19 weeks’ gestation from eight large health systems participating in the Vaccine Safety Datalink (VSD). The data was collected between Nov. ...
Biophysicists have designed a new cell-like transport system that represents an important milestone on the road to artificial cells.
Creating artificial cells with life-like characteristics out of a minimal set of components is a major goal of synthetic biology. Autonomous motion is a key capability here, and one that is difficult to reproduce in the test tube. A team led by physicist Erwin Frey, Professor of Statistical and Biological Physics at LMU, and Petra Schwille from the Max Planck Institute of Biochemistry, has now made ...
Every year, more than 40,000 women die of ovarian cancer in Europe. Ovarian cancer is a genetically very heterogeneous disease, which makes it exceptionally difficult to study and treat. The prognosis is particularly poor in ovarian high grade serous carcinoma (HGSC), a subtype of ovarian cancer. Less than 40% of patients with this subtype survive five years after their diagnosis.
The researchers were able to classify HGSC tumours into three groups on the basis of genomic changes. The groups differ in the intracellular signalling pathways, the ways in which the tumours grow, and response ...
The Collaborative Research Centre, to be known as HYP*MOL, will bring together 29 professors and early career researchers from both universities, as well as other external research partners, to study electron and nuclear spin hyperpolarization in molecular systems.
“This funding is both a cause for celebration and a great incentive for everyone involved,” says Professor Eva Inés Obergfell, Rector of Leipzig University. “Hyperpolarization is an exciting and rapidly evolving field of research. I believe that our research team will contribute new insights that will be appreciated at an international level.” Leipzig University is now involved ...
